Susan Altschuller - 01 Jun 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Chief Financial Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Jun 2023
Net transactions value
$0
Form type
4
Filing time
05 Jun 2023, 20:15:04 UTC
Previous filing
19 May 2023
Next filing
07 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +124,168 $0.000000 124,168 01 Jun 2023 Common Stock 124,168 $32.55 Direct F1
transaction CERE Restricted Stock Units Award $0 +30,721 $0.000000 30,721 01 Jun 2023 Common Stock 30,721 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on June 1, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3 The RSUs vest in four equal annual installments on each of June 1, 2024, June 1, 2025, June 1, 2026 and June 1, 2027, subject to the Reporting Person's continued service on each such vesting date.